Skip to main content

Cibinqo Disease Interactions

There are 6 disease interactions with Cibinqo (abrocitinib).

Major

Abrocitinib (applies to Cibinqo) cardiovascular disease

Major Potential Hazard, Moderate plausibility. Applicable conditions: Smoking, Heart Disease

Major adverse cardiovascular events such as cardiovascular death, myocardial infarction, and non-fatal stroke were observed in clinical studies with abrocitinib. Patients over 50 years old, current or past smokers, and patients with at least one cardiovascular risk factor were shown to have a higher risk. Consider the risks and benefits for each patient prior to initiating therapy with this drug, particularly in those that have cardiovascular risk factors including smoking.

Switch to professional interaction data

Major

Abrocitinib (applies to Cibinqo) infections

Major Potential Hazard, Moderate plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral

Serious infections leading to hospitalization or death, including tuberculosis (TB) and bacterial, invasive fungal, viral, and other opportunistic infections, have occurred in patients receiving JAK inhibitors such as abrocitinib. Abrocitinib should be avoided in patients with active serious infections, including localized infections. Treatment with abrocitinib is not recommended in patients with active TB, or in patients with active hepatitis B or C, as viral reactivation has been reported. Consider the risks and benefits of treatment prior to initiating therapy in patients with chronic or recurrent infections, exposed to tuberculosis, with a history of opportunistic infections, or underlying conditions that predispose to infection. Caution and close monitoring for signs and symptoms of infection is recommended during treatment.

Switch to professional interaction data

Major

Abrocitinib (applies to Cibinqo) malignancies

Major Potential Hazard, Moderate plausibility. Applicable conditions: Smoking, Neoplasia -- Estrogen Dependent, Lymphoma, Lung Cancer, History - Skin Cancer, Bladder Cancer

Malignancies, including lymphomas and lung cancers have been reported in patients receiving JAK inhibitors such as abrocitinib. Consider the benefits and risks for the individual patient prior to initiating or continuing therapy, particularly in patients with a known malignancy, and patients who are current or past smokers.

Switch to professional interaction data

Major

Abrocitinib -thrombosis

Major Potential Hazard, Moderate plausibility. Applicable conditions: Cardiovascular Disease

Deep venous thrombosis (DVT) and pulmonary embolism (PE) were observed in patients receiving abrocitinib. Patients 50 years of age and older with at least one cardiovascular risk factor, had higher rates of overall thrombosis, DVT, and PE. Avoid abrocitinib in patients that may be at increased risk of thrombosis.

Switch to professional interaction data

Moderate

Abrocitinib (applies to Cibinqo) liver dysfunction

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

Abrocitinib is not recommended for use in patients with severe hepatic impairment.

Switch to professional interaction data

Moderate

Abrocitinib (applies to Cibinqo) renal dysfunction

Moderate Potential Hazard, Moderate plausibility.

Abrocitinib is not recommended for use in patients with severe renal impairment (eGFR less than 30 mL/min) and end-stage renal disease (eGFR less than 15 mL/min).

Switch to professional interaction data

Cibinqo drug interactions

There are 564 drug interactions with Cibinqo (abrocitinib).

Cibinqo alcohol/food interactions

There is 1 alcohol/food interaction with Cibinqo (abrocitinib).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer